Envista Beats Q2 Estimates, Lifts 2026 Outlook on Broad-Based Growth
NVST sits 43% above its 52-week low of $18.77 on elevated volume (2.1× avg).
Summary
Envista delivered a strong Q2, with sales of $730.5M beating the $716M consensus and adjusted EPS surging 58% to $0.41. Both segments grew—Equipment & Consumables up 8.5%, Specialty Products up 3.1%—driving margin expansion. Management raised full-year guidance across the board: core sales growth now seen at 3.5%-4.5% (from 2%-4%), adjusted EBITDA growth at 11%-14% (from 7%-13%), and adjusted EPS at $1.50-$1.55 (from $1.35-$1.45). This follows a strong Q1 and a new $300M buyback program announced in May, reinforcing the turnaround narrative. The stock, trading at 18x forward earnings, could re-rate if execution continues.
At the time of this announcement, NVST was trading at $26.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $18.77 to $30.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.